Source comparison
CJC-1295 No DAC & Ipamorelin: Peptide Research Tools Comparison
CJC-1295 no DAC GHRH analogue. Extends endogenous GHRH half-life ~30 minutes 90–120 minutes post-injection None 100–200 mcg/day Evening (aligns with nocturnal GH) Ipamorelin Selective ghrelin mimetic (GHS-R1a agonist) ~2 hours 60–90 minutes post-injection None
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC
- GHRH analogue. Extends endogenous GHRH half-life
- ~30 minutes
- 90–120 minutes post-injection
- None
- 100–200 mcg/day
- Evening (aligns with nocturnal GH)
- Ipamorelin
- Selective ghrelin mimetic (GHS-R1a agonist)
- ~2 hours
- 60–90 minutes post-injection
- None (selective for GH only)
- 100–300 mcg/day
- Evening or pre-sleep
- CJC-1295 with DAC
- GHRH analogue with albumin-binding complex
- 6–8 days
- Sustained elevation (non-pulsatile)
- None directly, but chronic elevation disrupts cortisol rhythm
- 1–2 mg/week
- Not recommended for aging research
- GHRP-6
- Non-selective ghrelin mimetic
- ~20 minutes
- 45–60 minutes
- Increases cortisol and prolactin
- 100–300 mcg/dose
- Morning (offsets cortisol spike)
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- 24 hours
- Sustained low-level elevation
- Moderate cortisol increase
- 10–25 mg/day
- Evening (can disrupt sleep if dosed AM)